Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Korea's Celltrion Banks On Increasing Profits Resulting From New Focus On Biosimilars

This article was originally published in PharmAsia News

Executive Summary

SEOUL - Biopharmaceutical firm Celltrion posted a record performance in the most recent quarter due to the company's shift in focus from contract manufacturing to producing biosimilars

You may also be interested in...



Jordanian FDA Drug Director Laila Jarrar On Collaborations With Korean Regulators To Spur Biologics Growth - An Interview With PharmAsia News

The fast-growing pharmaceutical market in the Middle East has seen an increasing demand for regulators to step up to new challenges such as biologics and biosimilars, and to answer the call they are enhancing collaborations with leading health authorities around the world.

Jordanian FDA Drug Director Laila Jarrar On Collaborations With Korean Regulators To Spur Biologics Growth - An Interview With PharmAsia News

The fast-growing pharmaceutical market in the Middle East has seen an increasing demand for regulators to step up to new challenges such as biologics and biosimilars, and to answer the call they are enhancing collaborations with leading health authorities around the world.

Korea's Celltrion and Sanofi-Aventis In Line With 2008 Strategic Alliance For Monoclonal Antibodies

SEOUL - Despite Celltrion's claims that it is shifting away from its contract manufacturing business to focus on biosimilars, the company revealed an ongoing deal with Sanofi-Aventis for clinical materials and process development for monoclonal antibody therapeutics and announced the near completion of its CMO plant

Related Content

Latest News
See All
UsernamePublicRestriction

Register

SC075499

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel